GILD

125.97

0.29% -0.37

시장 영업 전: 127.49 1.52 +1.21%

길리어드 사이언스 (GILD)

개요 뉴스 가격 이력 옵션 체인 Financials GILD 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$126.34

열려 있는:

$127.275

하루 거래량:

6.37M

Relative Volume:

0.92

시가총액:

$156.40B

수익:

$29.79B

순이익/손실:

$9.22B

주가수익비율:

17.14

EPS:

7.3494

순현금흐름:

$10.23B

1주 성능:

+0.65%

1개월 성능:

-3.91%

6개월 성능:

+2.63%

1년 성능:

+12.75%

1일 변동 폭

$125.12

$127.62

1주일 범위

$123.67

$128.86

52주 변동 폭

$107.75

$157.29

길리어드 사이언스 Stock (GILD) Company Profile

명칭

Gilead Sciences Inc

부문

Healthcare (1092)

산업

Drug Manufacturers - General (20)

전화

(650) 574-3000

주소

333 LAKESIDE DR, FOSTER CITY, CA

직원

17,000

트위터

@GileadSciences

다음 수익 날짜

2026-08-06

최신 SEC 제출 서류

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, MRK, NVS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
GILD Gilead Sciences Inc	125.97	156.86B	29.79B	9.22B	10.23B	7.3494
LLY Lilly Eli Co	1,191.74	1.07T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	253.98	611.36B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	251.06	444.60B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	125.37	317.37B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	154.14	299.04B	54.66B	13.58B	16.05B	7.0171

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-10	개시	Jefferies	Buy
2026-02-20	개시	Barclays	Equal Weight
2026-02-11	재확인	Needham	Buy
2026-01-07	재개	UBS	Buy
2025-11-24	재개	Truist	Buy
2025-11-13	개시	Scotiabank	Sector Outperform
2025-08-19	업그레이드	Daiwa Securities	Neutral → Outperform
2025-08-08	업그레이드	Truist	Hold → Buy
2025-07-25	업그레이드	Needham	Hold → Buy
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-03-04	재확인	Oppenheimer	Outperform
2025-02-18	업그레이드	Deutsche Bank	Hold → Buy
2025-02-13	업그레이드	DZ Bank	Hold → Buy
2025-01-10	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-11-14	개시	Citigroup	Buy
2024-11-08	다운그레이드	Maxim Group	Buy → Hold
2024-10-21	업그레이드	Leerink Partners	Market Perform → Outperform
2024-10-17	개시	Bernstein	Outperform
2024-10-07	업그레이드	Wells Fargo	Equal Weight → Overweight
2024-07-08	업그레이드	Raymond James	Mkt Perform → Outperform
2024-05-01	재확인	Maxim Group	Buy
2024-04-24	업그레이드	HSBC Securities	Reduce → Hold
2024-02-22	다운그레이드	Truist	Buy → Hold
2023-11-09	개시	Deutsche Bank	Hold
2023-09-08	업그레이드	BofA Securities	Neutral → Buy
2023-09-06	개시	HSBC Securities	Reduce
2023-07-24	재확인	Barclays	Equal Weight
2023-05-16	업그레이드	BMO Capital Markets	Market Perform → Outperform
2023-04-28	재개	Piper Sandler	Overweight
2023-01-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	재개	BofA Securities	Neutral
2022-12-09	다운그레이드	DZ Bank	Buy → Hold
2022-10-31	업그레이드	Barclays	Underweight → Equal Weight
2022-10-28	재확인	BMO Capital Markets	Market Perform
2022-10-28	재확인	Cowen	Outperform
2022-10-28	재확인	JP Morgan	Overweight
2022-10-28	재확인	Jefferies	Buy
2022-10-28	업그레이드	Piper Sandler	Neutral → Overweight
2022-10-28	재확인	RBC Capital Mkts	Outperform
2022-10-28	업그레이드	Truist	Hold → Buy
2022-10-28	재확인	Wells Fargo	Equal Weight
2022-10-04	업그레이드	JP Morgan	Neutral → Overweight
2022-07-13	개시	Cantor Fitzgerald	Neutral
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-02-28	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2022-02-02	재확인	BMO Capital Markets	Outperform
2022-02-02	재확인	BofA Securities	Neutral
2022-02-02	재확인	RBC Capital Mkts	Outperform
2022-02-02	재확인	Truist	Hold
2022-02-02	재확인	Wells Fargo	Equal Weight
2022-01-28	업그레이드	Argus	Hold → Buy
2022-01-06	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	재개	Wells Fargo	Equal Weight
2021-12-06	개시	Goldman	Neutral
2021-11-19	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-11-19	재개	Piper Sandler	Neutral
2021-10-20	재개	Cowen	Outperform
2021-07-30	재확인	BMO Capital Markets	Market Perform
2021-07-30	재확인	RBC Capital Mkts	Outperform
2021-04-01	업그레이드	Bernstein	Mkt Perform → Outperform
2021-03-30	업그레이드	Redburn	Neutral → Buy
2021-01-19	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	업그레이드	Guggenheim	Neutral → Buy
2020-11-03	재개	Morgan Stanley	Equal-Weight
2020-10-28	개시	UBS	Neutral
2020-09-30	재개	Jefferies	Buy
2020-09-15	업그레이드	Maxim Group	Hold → Buy
2020-07-31	재확인	Credit Suisse	Neutral
2020-07-31	재확인	Morgan Stanley	Equal-Weight
2020-07-31	재확인	Piper Sandler	Overweight
2020-07-31	재확인	RBC Capital Mkts	Outperform
2020-07-31	재확인	SunTrust	Hold
2020-07-31	재확인	Wells Fargo	Equal Weight
2020-07-20	업그레이드	Credit Suisse	Underperform → Neutral
2020-06-03	업그레이드	SVB Leerink	Mkt Perform → Outperform
2020-05-26	업그레이드	SunTrust	Sell → Hold
2020-05-01	다운그레이드	JP Morgan	Overweight → Neutral
2020-05-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2020-05-01	다운그레이드	SunTrust	Hold → Sell
2020-04-27	다운그레이드	UBS	Buy → Neutral
2020-04-20	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2020-04-20	다운그레이드	Wells Fargo	Overweight → Equal Weight
2020-04-17	다운그레이드	CFRA	Hold → Sell

모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

Jul 01, 2026

Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says - Law360

Jul 01, 2026

Gilead Sciences highlights its antiviral portfolio as a long-term growth driver - AD HOC NEWS

Jul 01, 2026

Jun 30, 2026

Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $168 - Moomoo

Jun 30, 2026

Gilead Sciences consensus picture, shares steady on NASDAQ - AD HOC NEWS

Jun 30, 2026

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - WSJ

Jun 30, 2026

Jun 29, 2026

Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com

Jun 29, 2026

Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch

Jun 29, 2026

Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector - ChartMill

Jun 29, 2026

Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell Top 200 Growth Benchmark - marketscreener.com

Jun 29, 2026

Gilead Sciences wins Trodelvy approvals, shares supported by oncology focus - AD HOC NEWS

Jun 29, 2026

Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000 Growth Benchmark - marketscreener.com

Jun 28, 2026

Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 1000 Dynamic Index - marketscreener.com

Jun 28, 2026

Enterprise value to revenue forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView

Jun 27, 2026

Gilead Sciences clears a fresh 12?month high, shares react to new FDA approval - AD HOC NEWS

Jun 27, 2026

Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative? - Yahoo Finance

Jun 27, 2026

Jun 26, 2026

Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe - Yahoo Finance

Jun 26, 2026

GILD News | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill

Jun 26, 2026

Price to book forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView

Jun 26, 2026

Price to earnings forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView

Jun 26, 2026

Gilead Sciences Inc (GILD) Shares Surge 3.3% -- What GF Score of 75 Tells Investors - GuruFocus

Jun 26, 2026

Gilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Jun 26, 2026

Gilead Sciences, Inc. Actuals & Estimates (VIE:GILD) - TradingView

Jun 26, 2026

Gilead Sciences, Inc. Actuals & Estimates (LSX:885823) - TradingView

Jun 26, 2026

Gilead Sciences, Inc. Actuals & Estimates (NASDAQ:GILD) - TradingView

Jun 26, 2026

Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results - Insider Monkey

Jun 26, 2026

Gilead Sciences consensus stays robust, analysts stick to Moderate Buy rating - AD HOC NEWS

Jun 26, 2026

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh - TradingView

Jun 26, 2026

Jun 25, 2026

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know - sharewise.com

Jun 25, 2026

Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer - Benzinga

Jun 25, 2026

Could Chemotherapy Soon Be Optional? AstraZeneca and Gilead Drugs Show Promise for Breast Cancer Patients - Health and Me

Jun 25, 2026

Gilead Sciences updates oncology pipeline, shares steady on NASDAQ - AD HOC NEWS

Jun 25, 2026

Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use - Yahoo Finance

Jun 25, 2026

Gilead Sciences secures key FDA cancer approval, shares trade near recent highs - AD HOC NEWS

Jun 25, 2026

Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer - BioSpace

Jun 25, 2026

Photo gallery, Gilead Sciences v Pain Relief Rx et al - Partnership for Safe Medicines

Jun 25, 2026

OP Asset Management Ltd Acquires Shares of 256,653 Gilead Sciences, Inc. $GILD - MarketBeat

Jun 25, 2026

New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer - MedCity News

Jun 25, 2026

Jun 24, 2026

Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer - marketscreener.com

Jun 24, 2026

GILD Receives FDA Approval for Trodelvy in Triple-Negative Breas - GuruFocus

Jun 24, 2026

FDA approves Gilead’s Trodelvy for first-line breast cancer By Investing.com - Investing.com Canada

Jun 24, 2026

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer - Gilead Sciences

Jun 24, 2026

Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail

Jun 24, 2026

Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC - Yahoo Finance Singapore

Jun 24, 2026

Astellas Padcev and Gilead's Trodelvy grab key EU approvals - pharmaphorum

Jun 24, 2026

5 Set-It-and-Forget-It Stocks to Buy Right Now - Insider Monkey

Jun 24, 2026

Jun 23, 2026

Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh Trade Ideas — BCBA:GILD.CI - TradingView

Jun 23, 2026